Behind the stellar industrial launch of Amylyx Prescribed drugs’ therapy for ALS lies an uncomfortable query: Does early success of the drug, referred to as Relyvrio, make it extra difficult, maybe unattainable, to drag it from the market if we discover out subsequent yr that it doesn’t work?
On Monday evening, Amylyx mentioned Relyvrio gross sales totaled $22 million in 2022 — a interval that covers barely a couple of calendar quarter given the drug’s U.S. approval final September. The corporate mentioned roughly 1,300 ALS sufferers have been on Relyvrio on the finish of December, and it expects that quantity to at the very least double by the tip of the primary quarter.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
